Abstract
Ovarian cancer has a poor prognosis, and screening methods have not been established. Biomarkers based on molecular genetic characteristics must be identified to develop diagnostic and therapeutic strategies for all cancer types, particularly ovarian cancer. The present study aimed to evaluate the usefulness of genetic analysis of cervical and endometrial liquid-based cytology (LBC) specimens for detecting somatic mutations in patients with ovarian cancer. The data of 19 patients with ovarian cancer treated between August 2019 and July 2022 were analyzed. LBC specimens from the cervix and endometrium of patients with preoperatively suspected ovarian cancer were collected, and genomic DNA was extracted from these LBC specimens and surgically removed cancer tissue sections for genetic analysis. Next-generation sequencing (NGS) analysis of cervical and endometrial LBC revealed genetic mutations similar to those in formalin-fixed, paraffin-embedded (FFPE) tissues in 42% of ovarian cancer cases, including negative cervical and endometrial cytology cases and early-stage cases. The pathogenic variants detected were PIK3CA (n=1), RB1 (n=1) and TP53 (n=6). In high-grade serous carcinoma (HGSC) cases, the diagnosis rate was 54.5%, which was higher than that of other histological types. In univariate analysis of patients with HGSC, the presence of serous tubal intraepithelial carcinoma tended to be associated with the detection of somatic mutations in LBC samples. NGS analysis of cervical and endometrial LBC samples revealed genetic variants similar to those in FFPE tissues from ovarian cancer cases and may be useful as a noninvasive screening method for detecting somatic mutations and classifying ovarian cancer.